A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-017-1200-4
Abstract: PurposeThe aim of this phase II study was to evaluate the efficacy and safety of two doses (10 and 5 mg) of olanzapine in combination with standard antiemetic treatment (aprepitant, palonosetron, and dexamethasone) for patients receiving… read more here.
Keywords: emesis; phase; cisplatin; study ... See more keywords
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002408
Abstract: Background: In this trial, we evaluated the safety and efficacy of olanzapine in children receiving highly emetogenic chemotherapy. Materials and Methods: In this study, patients aged 3 to 18 years were randomly assigned to either… read more here.
Keywords: olanzapine group; control; highly emetogenic; group ... See more keywords
Factors associated with neurokinin-1 receptor antagonist use among commercially insured cancer patients receiving highly emetogenic chemotherapy.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.5_suppl.24
Abstract: 24Background: Neurokinin-1 receptor antagonists (NK1RA) reduce chemotherapy-induced nausea/vomiting (CINV) among patients undergoing highly emetogenic chemotherapy (HEC). We evaluated factors associated with the use of NK1RA in patients treated with HEC. Methods: We performed a retrospective… read more here.
Keywords: chemotherapy; use; neurokinin receptor; factors associated ... See more keywords
Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2017.7043
Abstract: Purpose: Prevention of chemotherapy-induced nausea and vomiting is essential to preserve quality of life in patients with cancer receiving highly emetogenic chemotherapy (HEC). Recently, new drugs (eg, fosaprepitant, and the newer neurokinin-1 receptor antagonists [NK1RAs]… read more here.
Keywords: chemotherapy; use; patients receiving; receiving highly ... See more keywords